Tesamorelin vs. CJC-1295
Head-to-head comparison based on the profiles in the PepCycle library.
| Attribute | Tesamorelin | CJC-1295 |
|---|---|---|
| Class | Growth Hormone | Growth Hormone Peptides |
| Description | Tesamorelin is a synthetic analog of human growth hormone–releasing hormone (GHRH) and is FDA-approved for the reduction of excess visceral adipose tissue in adults with HIV-associated lipodystrophy. Beyond its approved indication, it has been investigated in metabolic, hepatic, and cognitive research contexts. Educational reference only; not medical advice. | A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life due to Drug Affinity Complex (DAC) technology. |
| Dose in studies | 1-2 mg per day | 1-2 mg per week (with DAC) or 100 mcg 2-3x daily (no DAC) |
| Frequency | Daily | Weekly (with DAC) or 2-3x daily (no DAC) |
| Half-life | 26-38 minutes | ~6-8 days (with DAC) |
| Cycle length | Continuous under medical supervision | 8-16 weeks on, 4-8 weeks off |
| Research level | 4/5 – Well researched | 2/5 – Limited research |
Tesamorelin: full profile · CJC-1295: full profile
Values from research literature – not medical advice.